Pell Bio-Med Technology (6949) has a market capitalization of approximately NT$66.2B, trading at NT
Pell Bio-Med Technology's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 24.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Pell Bio-Med Technology runs a net profit margin of -1702.4%, a gross margin of -61.1%, and an operating margin of -1823.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Pell Bio-Med Technology reported revenue of NT
Pell Bio-Med Technology does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Pell Bio-Med Technology carries a debt-to-equity ratio of 0.09x and a current ratio of 9.60x, with a market beta of 0.91. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Pell Bio-Med Technology (6949) the key facts are: market cap NT$66.2B, revenue NT
Get Pell Bio-Med Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.